BE568907A - - Google Patents
Info
- Publication number
- BE568907A BE568907A BE568907DA BE568907A BE 568907 A BE568907 A BE 568907A BE 568907D A BE568907D A BE 568907DA BE 568907 A BE568907 A BE 568907A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- chymotrypsin
- aqueous solution
- calcium
- alpha
- Prior art date
Links
- 108090000317 Chymotrypsin Proteins 0.000 claims description 34
- 229960002376 chymotrypsin Drugs 0.000 claims description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000007864 aqueous solution Substances 0.000 claims description 17
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 11
- 239000001639 calcium acetate Substances 0.000 claims description 11
- 229960005147 calcium acetate Drugs 0.000 claims description 11
- 235000011092 calcium acetate Nutrition 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 description 8
- 238000005057 refrigeration Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE568907A true BE568907A (cs) |
Family
ID=188069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE568907D BE568907A (cs) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE568907A (cs) |
-
0
- BE BE568907D patent/BE568907A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1175149B9 (fr) | Composition desinfectante a base de h2o2, acides et ions metalliques | |
| BE1005691A4 (fr) | Composition pharmaceutique a base de ranitidine et son procede de preparation. | |
| EP0316993B1 (fr) | Compositions pharmaceutiques contenant un dérivé de l'acide 3-hydroxybutanoique choisi parmi les oligomères de cet acide et les esters de cet acide ou de ces oligomères avec du 1,3-butanediol | |
| CN1798503A (zh) | 游霉素杀真菌剂的稳定水溶液 | |
| FR2753101A1 (fr) | Extrait d'algues, composition cosmetique comportant un tel extrait et utilisation de cet extrait en tant qu'agent antibacterien et/ou antifongique | |
| CN1899272A (zh) | 还原型辅酶q水溶液的稳定组合物 | |
| WO1995004592A1 (fr) | Compositions aqueuses concentrees d'alkylpolyglycosides et leurs utilisations | |
| EP0471129B1 (fr) | Solution stable d'hypochlorite de sodium | |
| BE568907A (cs) | ||
| CA2407584A1 (en) | Process for preparing chitosan particles | |
| EP0244315A1 (fr) | Procédé de préparation d'une solution pharmaceutique aqueuse d'un principe actif constitué par un acide organique | |
| CH644758A5 (fr) | Composition aqueuse stable a base de peroxyde de benzoyle. | |
| CH636888A5 (fr) | Heparines purifiees et leur preparation. | |
| US6740752B2 (en) | Process for preparing chitosan particles | |
| FR2556727A1 (fr) | Nouvelles compositions therapeutiques a base d'adn a haut poids moleculaire et leur procede de preparation | |
| FR2519552A1 (fr) | Procede pour stabiliser le lysozyme dans une composition liquide ou semi-liquide, et composition stabilisee a base de lysozyme | |
| Sirbu et al. | Rheological characterisation of collagen gels from marine resources of Black Sea and chlohexidine salt for using in Dental Medicine | |
| CA2396180C (fr) | Solution aqueuse stable de deoxyfructosazine | |
| CN108272649A (zh) | 一种含IgY的澄清漱口液及其制备方法 | |
| BE469075A (cs) | ||
| BE665076A (cs) | ||
| EP0437406A1 (fr) | Composition pharmaceutique sous forme de suspension aqueuse stable à base de sucralfate et d'une substance anti-acide ainsi que son procédé de préparation | |
| EP0116182A1 (fr) | Procédé de préparation d'acide p-butoxyphénylacéthydroxamique à l'état finement divisé | |
| CN118476997A (zh) | 一种壳聚糖溶液漱口水及其制备方法 | |
| JP2795423B2 (ja) | 皮膚用塗布剤 |